State Street Corp Trims Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

State Street Corp trimmed its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 11.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,476,292 shares of the biopharmaceutical company’s stock after selling 444,371 shares during the period. State Street Corp owned approximately 2.23% of Ocular Therapeutix worth $30,244,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Atlas Capital Advisors LLC acquired a new position in Ocular Therapeutix during the second quarter valued at $34,000. Amalgamated Bank raised its stake in shares of Ocular Therapeutix by 37.9% during the 2nd quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 1,481 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Ocular Therapeutix by 22.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 1,015 shares during the period. Capital Performance Advisors LLP purchased a new stake in shares of Ocular Therapeutix in the third quarter worth about $70,000. Finally, Algert Global LLC acquired a new stake in Ocular Therapeutix during the second quarter worth about $69,000. 59.21% of the stock is owned by hedge funds and other institutional investors.

Ocular Therapeutix Trading Up 0.6 %

Shares of OCUL stock opened at $8.50 on Friday. The company has a market cap of $1.34 billion, a price-to-earnings ratio of -6.44 and a beta of 1.19. The stock has a 50 day simple moving average of $9.98 and a 200-day simple moving average of $8.60. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. Ocular Therapeutix, Inc. has a 1-year low of $3.76 and a 1-year high of $11.77.

Insider Buying and Selling at Ocular Therapeutix

In other Ocular Therapeutix news, insider Jeffrey S. Heier sold 2,948 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $9.01, for a total transaction of $26,561.48. Following the completion of the transaction, the insider now owns 269,059 shares of the company’s stock, valued at $2,424,221.59. This represents a 1.08 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 3.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on OCUL shares. Scotiabank assumed coverage on Ocular Therapeutix in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $22.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Ocular Therapeutix in a research note on Tuesday, December 3rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $16.71.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.